Business Context and Reporting Period
This Form 8-K was filed by Element Solutions Inc on May 17, 2019. The report addresses the finalization of post-closing adjustments related to the sale of Arysta LifeScience Inc., which was completed on January 31, 2019.
Key Financial Metrics
- Final Purchase Price: $4,427,007,474
- Post-Closing Adjustments: $89,505,697 (payable by the Purchaser to the Company)
- Transaction Expense Reimbursement: $494,304
- Payment Deadline: On or before May 24, 2019
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these ongoing operational metrics.
Material Changes Versus Prior Period
The filing confirms an increase in the aggregate purchase price from the previously disclosed approximate amount of $4.2 billion to a finalized amount of $4,427,007,474. This change is attributable to the finalized Post-Closing Adjustments of $89,505,697.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, outlook, or management commentary regarding future operations. It strictly reports the conclusion of the financial settlement for the divestiture of Arysta LifeScience Inc. to subsidiaries of UPL Corporation Ltd.
Investor Verification Checklist
- Verify the receipt of the $89,505,697 post-closing adjustment payment by May 24, 2019.
- Confirm the receipt of the $494,304 transaction expense reimbursement.
- Review the impact of the finalized $4.427 billion proceeds on the company's balance sheet and liquidity position in subsequent filings.